Haruka Itakura
Assistant Professor of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (7)
AIMP1/2/3 correlates with angiogenesis pathway gene sets. Correlation between AIMP1/2/3 mRNA expression in 33 TCGA cancers and ( A ) 141 Panther pathway “angiogenesis gene set” and ( B ) 76 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway “VEGF Signaling pathway” gene set. The color map represents Pearson correlation coefficient R values. *asterisk represents statistically significant correlation ( P
Year:
2025
Bevacizumab treatment response is associated with specific AIMP CpG site methylation status in gliomas. A, Significant association between two CpG sites and astrocytoma ( n = 22) pathologic response to bevacizumab treatment. A Student t test P value B , Forest plots depicting Cox proportional hazards model univariate ( i ) and multivariate ( ii ) analysis for the effects of AIMP1/2/3 CpG methylation status in GBM ( n = 27) and astrocytoma ( n = 24).
Year:
2025
Spatial and cell type–specific expression of AIMP2 in GBM tumors. A, Spatial distribution of AIMP2 expression across tumor tissues in two representative GBM slides ( i : slide 334_T and ii : slide 268_T) analyzed using a spatial transcriptomic dataset. The heatmaps display homogeneous expression of AIMP2 with varying intensity from low (purple) to high (yellow), indicating the absence of localized expression hotspots. B, Violin plots representing AIMP2 expression across GBM cellular subtypes. i, AIMP2 expression in key GBM subtypes, including MES-like, AC-like, oligodendrocyte progenitor cell (OPC)–like, and neural progenitor cell (NPC)–like cells from a concatenated single-cell RNA-seq cohort (Kruskal–Wallis P = 2.32e−02). ii, AIMP2 expression across malignant GBM subtypes from a spatial transcriptomic dataset. (Kruskal–Wallis P = 1.32e−03).
Year:
2025
High AIMP mRNA expression subgroups are more responsive to antiangiogenic therapies. Kaplan–Meier survival analysis on retrospective clinical trials of recurrent GBM (REGOMA and BELOB trials). High expression sub-groups are stratified by median mRNA expressions of AIMP1/2/3 . A log-rank P value
Year:
2025
AIMP1 , AIMP2 , and AIMP3 are differentially expressed in glioma tissues. AIMP1/2/3 ( A ) mRNA (red bars: tumor samples; gray bars: normal samples) and ( B and C ) protein expression in TCGA-GBM, TCGA-LGG, and normal brain (GTEx) tissues. Data for ( B ) and ( C ) were collected from the Human Protein Atlas. A Student t test was used *, P
Year:
2025
Glioblastoma (GBM) is a highly vascularized, heterogeneous tumor, yet antiangiogenic therapies have yielded limited survival benefits. The lack of validated predictive biomarkers for treatment response stratification remains a major challenge. Aminoacyl tRNA synthetase complex–interacting multicomplex proteins ( AIMP ) 1/2/3 have been implicated in central nervous system diseases, but their roles in gliomas remain unexplored. We investigated their association with angiogenesis and their significance as predictive biomarkers for antiangiogenic treatment response. In this multi-cohort retrospective study, we analyzed glioma samples from The Cancer Genome Atlas, Chinese Glioma Genome Atlas, REMBRANDT, Gravendeel, BELOB, and REGOMA trials, and four single-cell transcriptomic datasets. Multiomic analyses incorporated transcriptomic, epigenetic, and proteomic data. Kaplan–Meier and Cox proportional hazards models were used to assess the potential prognostic value of AIMP s in heterogeneous and homogeneous treatment groups. Using single-cell transcriptomics, we explored spatial and cell type–specific AIMP2 expression in GBM. AIMP1/2/3 expressions correlated significantly with angiogenesis across The Cancer Genome Atlas cancers. In gliomas, AIMP s were upregulated in tumor versus normal tissues, higher- versus lower-grade gliomas, and recurrent versus primary tumors ( P AIMP2 subgroups had improved response to therapies in GBM [REGOMA: HR, 4.75 (1.96–11.5), P P = 0.015]. AIMP2 - cg04317940 methylation emerged as a clinically applicable stratification marker. Single-cell analysis revealed homogeneous AIMP2 expression in tumor tissues, particularly in astrocyte-like cells, suggesting a mechanistic link to tumor angiogenesis. These findings provide novel insights into the role of AIMP s in angiogenesis, offering improved patient stratification and therapeutic outcomes in recurrent GBM. Significance: This study identifies AIMP2 as a novel biomarker predictive of antiangiogenic treatment response in recurrent GBM. Through multiomic and single-cell analyses, AIMP2 is shown to be upregulated in aggressive gliomas and linked to angiogenesis. Its expression and methylation status offer a clinically applicable stratification tool, enabling more personalized therapeutic approaches and improved outcomes in patients receiving antiangiogenic therapies.
Year:
2025
AIMP s are associated with tumor aggressiveness, recurrence, and prognosis. AIMP mRNA expression levels in ( Ai ) low-grade (II; n = 103) and high-grade (III and IV; n = 218) gliomas ( P values 0.011, AIMP1 , AIMP2 , and AIMP3 , respectively), and ( Aii ) primary ( n = 229) and recurrent gliomas ( n = 62) in CGGA dataset ( P values 0.058, P P AIMP1 , AIMP2 , and AIMP3 , respectively). A Mann–Whitney test P value B, Kaplan–Meier survival curves depicting prognostic effects of AIMP1/2/3 mRNA expressions in CGGA, TCGA, REMBRANDT, and Gravendeel cohorts of GBM. Red = high expression and green = low expression based on median cutoff; A log-rank P value
Year:
2025
Collaborators (2)
Olivier Gevaert
Assistant Professor
Stanford University
Yuanning Zheng
Assistant Professor
University of Houston
Make your next move.
Prepare your application
Review drafts before you send them.